Advanced search×

Controlled self-assembly of monodisperse niosomes by microfluidic hydrodynamic focusing.

Langmuir 26(11):8559-66 (2010) PMID 20146467

Niosomes are synthetic membrane vesicles formed by self-assembly of nonionic surfactant, often in a mixture with cholesterol and dicetyl phosphate. Because of their inner aqueous core and bilayer membrane shell, niosomes are commonly used as carriers of treatment agents for pharmaceutical and cosmetic applications or contrast agents for clinical imaging applications. In those applications, niosomes are considered as a more economical and stable alternative to their biological counterpart (i.e., liposomes). However, conventional bulk method of niosome preparation requires bulk mixing of two liquid phases, which is time-consuming and not well-controlled. Such mixing conditions often lead to large niosomes with high polydispersity in size and thus affect the consistency of niosome dosage or imaging quality. In this study, we present a new method of niosome self-assembly by microfluidic hydrodynamic focusing to improve on the size and size distributions of niosomes. By taking advantage of the rapid and controlled mixing of two miscible fluids (i.e., alcohol and water) in microchannels, we were able to obtain in seconds nanoscaled niosomes with approximately 40% narrower size distributions compared to the bulk method. We further investigated different parameters that might affect on-chip assembly of niosomes, such as (1) conditions for the microfluidic mixing, (2) chemical structures of the surfactant used (i.e., sorbitan esters Span 20, Span 60, and Span 80), and (3) device materials for the microchannel fabrication. This work suggests that microfluidics may facilitate the development and optimization of biomimetic colloidal systems for nanomedicine applications.

DOI: 10.1021/la904616s
Version: za2963e q8zaa q8zb1 q8zcb q8zd5 q8zef q8zf2 q8zgb

Similar articles you may find interesting…

  1. Preparation, in vitro and in vivo evaluation of liposomal/niosomal gel delivery systems for clotrimazole.

    Drug Dev Ind Pharm 31(4-5):375-83 (2005) PMID 16093203

    Clotrimazole, which is an imidazole derivative antifungal agent, was widely used for the treatment of mycotic infections of the genitourinary tract. To develop alternative formulation for the vaginal administration of clotrimazole to provide sustained and controlled release of appropriate drug for l...
  2. Preparation and characterization of EP-liposomes and Span 40-niosomes.

    Pharmazie 61(3):208-12 (2006) PMID 16599261

    Clotrimazole, an imidazole derivative antifungal agent, has been widely used for the treatment of mycotic infections of the genitourinary tract. In order to develop alternative formulations for the vaginal administration of clotrimazole which would provide sustained and controlled release of the app...
  3. Clotrimazole, an antimycotic drug, inhibits the sarcoplasmic reticulum calcium pump and contractile function in heart muscle.

    J Biol Chem 273(43):28032-9 (1998) PMID 9774419

    Clotrimazole (CLT), an antimycotic drug, has been shown to inhibit proliferation of normal and cancer cell lines and its systemic use as a new tool in the treatment of proliferative disorders is presently under scrutiny (Benzaquen, L. R., Brugnara, C., Byers, H. R., Gattoni-Celli, S., and Halperin,...